You are here

The United States Attorney's Office

Eastern District of Pennsylvania

Eli Lilly Plea Settlement

Eli Lilly and Company (Eli Lilly) and the government (the Office of the United States Attorney for the Eastern District of Pennsylvania and the Office of Consumer Litigation of the Department of Justice) entered into an agreement whereby Eli Lilly agrees to plead guilty to the introduction into interstate commerce of quantities of its drug, Zyprexa, that were misbranded in violation of 21 U.S.C. §§ 331(a), 333(a)(1) and 352(f)(1). Specifically, Eli Lilly will plead guilty to promoting Zyprexa in elderly populations as treatment for dementia, including Alzheimer's dementia, between September 1999 and March 31, 2001.

The entry of plea and sentencing hearing in this matter will be held before the Honorable Robert F. Kelly on Friday, January 30, 2009, at 10:00 a.m. in Courtroom 11B, 11th floor of the United States District Court, United States Courthouse, 601 Market Street, Philadelphia, Pennsylvania. The case has been assigned the criminal docket number 09-020.

All government filings, both criminal and civil, are available for your convenience on the following links:

• Information
• Guilty Plea Agreement
• Government's Memorandum For Entry Of Plea and Sentencing
• Corporate Integrity Agreement
• Settlement Agreement
• Government's Supplemental Motion in Anticipation of Sentencing and Judgment and Order of Forfeiture

To see the statement issued by Acting United States Attorney Laurie Magid, click here.
To see a press release issued by the United States Attorney’s Office for the Eastern District of Pennsylvania, click here.
To see a press release issued by the United States Attorney’s Office for the Eastern District of Pennsylvania, click here.

Updated December 15, 2014

Was this page helpful?

Was this page helpful?
Yes No